Clinical Trial Update: Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors [Phase 1]

View source ↗

Summary

A Phase 1 trial is evaluating the addition of Elimusertib, an ATR inhibitor, to gemcitabine for advanced pancreatic and ovarian cancers and other solid tumors; …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fallopian Tube Cancer
• Ovarian Cancer
• Pancreatic Cancer
• Peritoneal Cancer

Drugs mentioned

• Elimusertib (Elimusertib)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Status: ACTIVE_NOT_RECRUITING